My research interests primarily lie in the fields of cancer biology, particularly ovarian cancer, and the molecular mechanisms underlying drug resistance. I have extensively studied the role of critical genes in chemoresistance, as evidenced by my publication on EMP1's role in cisplatin resistance in ovarian cancer (Zeng et al., Cancer Medicine, 2023). Additionally, I have explored targeted therapies for ovarian cancer, focusing on proteins such as Nectin-4 (Wang et al., Yangtze Medicine, 2022). Another significant area of my research is the role of apoptosis-inducing ligands and their receptors in various physiological and pathological conditions. For instance, I have investigated the involvement of TRAIL in early pregnancy (Lu et al., Analytical and Quantitative Cytopathology and Histopathology, 2022) and its abnormal expression in decidual tissues during early pregnancy loss due to Chlamydia trachomatis infection (Lu et al., Reproductive Sciences, 2016). My work also extends to respiratory diseases, where I have examined prognostic factors in severe COVID-19 pneumonia with acute respiratory distress syndrome (Wang et al., Yangtze Medicine, 2021). In the realm of prenatal diagnostics, I have contributed to optimizing amniotic fluid culture systems for chromosome examination (Xin et al., Journal of Yangtze University, 2020). Furthermore, I have delved into the biochemical markers for early diagnosis of diabetic nephropathy (Dong et al., Laboratory Medicine and Clinic, 201